search
Back to results

Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.

Primary Purpose

Influenza

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
CAIV-T
TIV
Placebo
Sponsored by
MedImmune LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Influenza

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Subjects had to have been at least 18 years of age and less than 65 years of age at the time informed consent was obtained; Women of child-bearing potential had to use reliable methods of hormonal and/or nonhormonal contraception (which includes cervical cap, diaphragm, condoms with spermicide or IUD) during sexual intercourse throughout the entire study period; a negative urine pregnancy test (with detection limit of less than or equal to 25mIU/mL) no more than 24 hours prior to vaccine administration; and agreed to avoid pregnancy during participation in the study. A urine pregnancy test was also conducted at the completion of study participation. Females who were surgically sterile at time of enrollment were not required to undergo pregnancy testing. who were determined by medical history, physical examination and clinical judgement to be eligible for the study. who provided written informed consent after the nature of the study has been explained; who were available for one month duration of the trial (from enrollment to study completion); who could be reached by study staff for the post-vaccination contact [telephone, clinic or home visit]. Exclusion Criteria: who were perceived to be unavailable or difficult to contact for evaluation or study visits during the study period; with a known or suspected disease of the immune system or those receiving immunosuppressive therapy, including systemic corticosteroids and intranasal steroids; or cytotoxic agents; who had an immunosuppressed or an immunocompromised individual living in the same household; who had a documented history of hypersensitivity to egg or egg protein or any other component of the study vaccine or placebo; who received any commercially-available or investigational injected influenza vaccine in the 6 months prior to enrollment, or a non-study influenza vaccine since enrollment; who previously received an intranasally administered influenza vaccine; who had any medical conditions that, in the opinion of the investigator, might interfere with interpretation of the study results;

Sites / Locations

  • David M. Radin, MD

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Placebo Comparator

Arm Label

Cold-adapted influenza vaccine (CAIVT)

Trivalent inactivated vaccine (TIV)

Placebo

Arm Description

A single intranasal dose of 10^7 fluorescent focus units.

A single dose of commercially available Flushield was administered intramuscularly.

The 0.2 mL administered intranasally.

Outcomes

Primary Outcome Measures

Kinetics of the hemagglutination inhibition antibody response to each vaccine strain
The geometric mean titers for each strain between Day 0 and 28 were examined.

Secondary Outcome Measures

Expression of IgA in nasal wash and saliva swab samples
Nasal wash and saliva swab IgA antibody titers were expressed as the ratio of specific to total IgA.
Expression of B-cells in peripheral blood
The B-cell ELISPOT assays are designed to detect B-cells in the peripheral blood that are actively secreting influenza strain-specific IgG or IgA antibody.
Number of CD3+ peripheral blood mononuclear cells secreting interferon gamma
The number of CD3+ peripheral blood mononuclear cells (PBMCs), i.e., T-cells, secreting IFN-γ prior to and after vaccination following in vitro stimulation of these cells using the IFN-γ ELISPOT assay.
Number of subjects with local reactions
Local injection site reactions were collected from subjects in the TIV treatment group only.
Number of subjects with systemic reactions
Each study subject collected prompted reactogenicity events on a diary card worksheet for 7 days (study days 0 - 6) following vaccination.
Number of subjects with adverse events
An Adverse Event (or Adverse Experience, AE) was any untoward, undesired or unexpected clinical event in the form of signs, symptoms, disease or laboratory or physiological observations occurring (in a human being) in a temporal relationship to the use of a WLV product, regardless of causal relationship.

Full Information

First Posted
September 12, 2005
Last Updated
February 13, 2012
Sponsor
MedImmune LLC
Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
search

1. Study Identification

Unique Protocol Identification Number
NCT00192309
Brief Title
Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.
Official Title
A Randomized, Open-Label, Placebo-Controlled Trial to Investigate the Kinetics of the Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent,Types A & B, Live, Cold-Adapted (CAIV-T) in Healthy Adults Aged 18 to <65 Years.
Study Type
Interventional

2. Study Status

Record Verification Date
February 2012
Overall Recruitment Status
Completed
Study Start Date
September 2001 (undefined)
Primary Completion Date
December 2001 (Actual)
Study Completion Date
December 2001 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
MedImmune LLC
Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary objective of this study was to perform a variety of assays on blood, serum, nasal wash and cell samples obtained from healthy adult subjects for the purposes of developing assays for application in the further investigation of immune responses generated by influenza virus vaccine, trivalent, types A & B, live, cold-adapted (liquid formulation CAIV-T; Wyeth, Marietta, PA).
Detailed Description
This was a randomized, open-label, placebo-controlled, outpatient study carried out in healthy adults 18 to < 65 years of age. The study was designed to evaluate the kinetics of the immune responses generated by each of the study products in order to determine the best sampling time for future studies. Subjects were randomized in a 1:1:1 ratio to receive a single dose of either CAIV-T, inactivated influenza virus vaccine (TIV), or placebo.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Influenza

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
31 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cold-adapted influenza vaccine (CAIVT)
Arm Type
Experimental
Arm Description
A single intranasal dose of 10^7 fluorescent focus units.
Arm Title
Trivalent inactivated vaccine (TIV)
Arm Type
Active Comparator
Arm Description
A single dose of commercially available Flushield was administered intramuscularly.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
The 0.2 mL administered intranasally.
Intervention Type
Biological
Intervention Name(s)
CAIV-T
Other Intervention Name(s)
FluMist
Intervention Description
Liquid CAIV-T vaccine for this study consisted of three cold-adapted, attenuated, reassortant strains representing the hemagglutinin (HA) and neuraminidase (NA) antigens of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2) and B/Yamanashi/166/98 influenza virus strains. The reassortant vaccine strains were grown in specific pathogen-free (SPF) eggs and the allantoic fluid, which contained virus, was harvested, concentrated and purified. Each dose of CAIV-T used in this study was formulated to contain approximately 107 FFU of each of the 6:2 influenza reassortant vaccine strains.
Intervention Type
Biological
Intervention Name(s)
TIV
Other Intervention Name(s)
Flushield
Intervention Description
TIV in this study consisted of Flushield™, manufactured by Wyeth Vaccines, Marietta, PA, USA. Each 0.5 mL dose contained no less than 15 ug of the hemagglutinin antigens from each of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Yamanashi/166/98 strains, making TIV in this study antigenically matched to the influenza strains contained in CAIV-T.
Intervention Type
Biological
Intervention Name(s)
Placebo
Intervention Description
Placebo in this study consisted of physiological saline. The total volume of 0.2 mL was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
Primary Outcome Measure Information:
Title
Kinetics of the hemagglutination inhibition antibody response to each vaccine strain
Description
The geometric mean titers for each strain between Day 0 and 28 were examined.
Time Frame
Day 0-28
Secondary Outcome Measure Information:
Title
Expression of IgA in nasal wash and saliva swab samples
Description
Nasal wash and saliva swab IgA antibody titers were expressed as the ratio of specific to total IgA.
Time Frame
Days 0-28
Title
Expression of B-cells in peripheral blood
Description
The B-cell ELISPOT assays are designed to detect B-cells in the peripheral blood that are actively secreting influenza strain-specific IgG or IgA antibody.
Time Frame
Days 0-28
Title
Number of CD3+ peripheral blood mononuclear cells secreting interferon gamma
Description
The number of CD3+ peripheral blood mononuclear cells (PBMCs), i.e., T-cells, secreting IFN-γ prior to and after vaccination following in vitro stimulation of these cells using the IFN-γ ELISPOT assay.
Time Frame
Days 0-28
Title
Number of subjects with local reactions
Description
Local injection site reactions were collected from subjects in the TIV treatment group only.
Time Frame
Days 0-7
Title
Number of subjects with systemic reactions
Description
Each study subject collected prompted reactogenicity events on a diary card worksheet for 7 days (study days 0 - 6) following vaccination.
Time Frame
Days 0-7
Title
Number of subjects with adverse events
Description
An Adverse Event (or Adverse Experience, AE) was any untoward, undesired or unexpected clinical event in the form of signs, symptoms, disease or laboratory or physiological observations occurring (in a human being) in a temporal relationship to the use of a WLV product, regardless of causal relationship.
Time Frame
Days 0-7

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Subjects had to have been at least 18 years of age and less than 65 years of age at the time informed consent was obtained; Women of child-bearing potential had to use reliable methods of hormonal and/or nonhormonal contraception (which includes cervical cap, diaphragm, condoms with spermicide or IUD) during sexual intercourse throughout the entire study period; a negative urine pregnancy test (with detection limit of less than or equal to 25mIU/mL) no more than 24 hours prior to vaccine administration; and agreed to avoid pregnancy during participation in the study. A urine pregnancy test was also conducted at the completion of study participation. Females who were surgically sterile at time of enrollment were not required to undergo pregnancy testing. who were determined by medical history, physical examination and clinical judgement to be eligible for the study. who provided written informed consent after the nature of the study has been explained; who were available for one month duration of the trial (from enrollment to study completion); who could be reached by study staff for the post-vaccination contact [telephone, clinic or home visit]. Exclusion Criteria: who were perceived to be unavailable or difficult to contact for evaluation or study visits during the study period; with a known or suspected disease of the immune system or those receiving immunosuppressive therapy, including systemic corticosteroids and intranasal steroids; or cytotoxic agents; who had an immunosuppressed or an immunocompromised individual living in the same household; who had a documented history of hypersensitivity to egg or egg protein or any other component of the study vaccine or placebo; who received any commercially-available or investigational injected influenza vaccine in the 6 months prior to enrollment, or a non-study influenza vaccine since enrollment; who previously received an intranasally administered influenza vaccine; who had any medical conditions that, in the opinion of the investigator, might interfere with interpretation of the study results;
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert Walker, MD
Organizational Affiliation
MedImmune LLC
Official's Role
Principal Investigator
Facility Information:
Facility Name
David M. Radin, MD
City
Stamford
State/Province
Connecticut
ZIP/Postal Code
06905
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.

We'll reach out to this number within 24 hrs